Work with thought leaders and academic experts in hepatology

Companies can greatly benefit from collaborating with an academic researcher specializing in hepatology. Here are a few reasons why:

Researchers on NotedSource with backgrounds in hepatology include Dr. Shilpa Patil, Ph.D, Mounika Gudeppu, Luke Connelly, Roshonda Jones, Giuliana Noratto, James Boot, PhD, Dana Walsh, Ph.D., Marina Baretti, Leo R Fitzpatrick PhD, Elham Shirvani-Dastgerdi, Emma Hernandez-Sanabria, and Pranshu Sahgal, Ph.D..

Dr. Shilpa Patil, Ph.D

Vancouver, British Columbia, Canada
10 Years Experience
PhD & Postdoc level expertise in Cancer Research
Education

University of Göttingen

Ph.D, Cancer Research / June, 2020

Göttingen

Manipal Academy of Higher Education

MSc, Regenerative Medicine / August, 2014

Manipal

Manipal Academy of Higher Education

BSc, Biotechnology / August, 2012

Manipal
Experience

University of British Columbia

Postdoctoral Research Fellow / January, 2021 — July, 2023

University of Gottingen

Postdoctoral Researcher / July, 2020 — December, 2020

JNCASR

Research Assistant / September, 2014 — February, 2016

Most Relevant Research Expertise
Hepatology
Other Research Expertise (11)
Cancer
epigenetics
development
Oncology
Cancer Research
And 6 more
About
Dr. Shilpa Patil is a highly experienced cancer researcher with a strong background in Preclinical studies. She received her Ph.D. in Molecular Medicine from the University of Göttingen in 2020, where she focused on developing novel treatments for pancreatic cancer. Prior to that, she completed her MSc in Regenerative Medicine from Manipal University in 2014 and her BSc in Biotechnology from the same institution in 2012. With over 6 years of research experience, Dr. Patil has worked at prestigious institutions such as the University of British Columbia, University of Göttingen and JNCASR. Her expertise lies in the areas of cancer biology, epigenetics, cell and molecular biology, and regenerative medicine. She has published numerous research articles in reputed journals and has presented her work at various international conferences. Dr. Patil is a dedicated and passionate scientist, committed to using her knowledge and skills to contribute to the fight against cancer. She is driven by her curiosity to unravel complex biological processes and her desire to make a positive impact in the field of cancer research. She is also driven to bridge the academia-industry gap.
Most Relevant Publications (4+)

20 total publications

NFATc1 Is a Central Mediator of EGFR-Induced ARID1A Chromatin Dissociation During Acinar Cell Reprogramming

Cellular and Molecular Gastroenterology and Hepatology / Jan 01, 2023

Zhang, Z., Wang, X., Hamdan, F. H., Likhobabina, A., Patil, S., Aperdannier, L., Sen, M., Traub, J., Neesse, A., Fischer, A., Papantonis, A., Singh, S. K., Ellenrieder, V., Johnsen, S. A., & Hessmann, E. (2023). NFATc1 Is a Central Mediator of EGFR-Induced ARID1A Chromatin Dissociation During Acinar Cell Reprogramming. Cellular and Molecular Gastroenterology and Hepatology, 15(5), 1219–1246. https://doi.org/10.1016/j.jcmgh.2023.01.015

EZH2 controls PDAC plasticity by regulating differentiation genes

Pancreatology / Jun 01, 2019

Patil, S., Najafova, Z., Kari, V., Wang, X., Bohnenberger, H., Kopp, W., Spitalieri, J., Neesse, A., Ellenrieder, V., Johnsen, S., & Hessmann, E. (2019). EZH2 controls PDAC plasticity by regulating differentiation genes. Pancreatology, 19, S11. https://doi.org/10.1016/j.pan.2019.05.021

Impact of cytosolic 5'-nucleotidase 1A on chemotherapeutic resistance in pancreatic cancer

Pancreatology / Jun 01, 2018

Patzak, M. S., Hessmann, E., Kari, V., Kitz, J., Patil, S., Richards, F. M., Jodrell, D. I., Johnsen, S. A., Ellenrieder, V., & Neesse, A. (2018). Impact of cytosolic 5’-nucleotidase 1A on chemotherapeutic resistance in pancreatic cancer. Pancreatology, 18(4), S91. https://doi.org/10.1016/j.pan.2018.05.247

Role of oncogenic EZH2 histone methyltransferase activity in PDAC cellular plasticity

Pancreatology / Jul 01, 2017

Patil, S., Witte, H., Neesse, A., Johnsen, S., Ellenrieder, V., & Hessmann, E. (2017). Role of oncogenic EZH2 histone methyltransferase activity in PDAC cellular plasticity. Pancreatology, 17(3), S41. https://doi.org/10.1016/j.pan.2017.05.128

See Full Profile

Mounika Gudeppu

5 Years Experience
Ph.D. holder in Pharmacology and Toxicology, holded an SME position in HCL Tech Medical device Biocompatibility domain
Education

University of Madras

Ph.D., Pharmacology and Toxicology / April, 2021

Chennai

Kakatiya University

M-Pharm, Pharmacology / February, 2015

Warangal

Kakatiya University

B-Pharmacy / June, 2012

Warangal
Experience

HCLTech

SME / March, 2019 — July, 2022

Biocompatibility specialist

Most Relevant Research Expertise
Hepatology
Other Research Expertise (12)
medical science
Pharmacology
Gastroenterology
Endocrinology, Diabetes and Metabolism
Obstetrics and Gynecology
And 7 more
About
I am a subject matter expert in medical device biocompatibility and toxicology with 7 years of experience in preclinical (invitro and invivo) and experimental pharmacology and toxicology in industry and academia. I worked with several anticancer drugs and submitted a proposal about gut microbiota's influence on overall health including cancer
Most Relevant Publications (1+)

16 total publications

The Successful Use of N-Acetyl-cysteine to Treat Sorafenib-Induced Hepatotoxicity

American Journal of Gastroenterology / Oct 01, 2017

Hasan, M., Alukal, J., Tarsitano, J., & Choi, E. (2017). The Successful Use of N-Acetyl-cysteine to Treat Sorafenib-Induced Hepatotoxicity: 2261. American Journal of Gastroenterology, 112, S1243. https://doi.org/10.14309/00000434-201710001-02262

See Full Profile

Luke Connelly

25 Years Experience
Professor of Health Economics, The University of Queensland, CBEH
Education

University of Queensland

PhD, School of Economics / June, 1999

Brisbane, Queensland, Australia

University of Queensland

Master of Economic Studies, School of Economics / December, 1993

Brisbane, Queensland, Australia

University of Queensland

Bachelor of Arts (Economics), School of Economics / November, 1991

Brisbane, Queensland, Australia
Experience

The University of Bologna

Professor

The University of Queensland

Professor of Health Economics / May, 2015 — Present

Professor of Health Economics and Associate Director / January, 2008 — August, 2015

Associate Professor and Associate Director / May, 2003 — December, 2007

Queensland University of Technology

Senior Lecturer in Economics / May, 2000 — April, 2003

Lecturer / January, 1998 — April, 2000

Most Relevant Research Expertise
Hepatology
Other Research Expertise (42)
Health economics
insurance
Public Health, Environmental and Occupational Health
Safety, Risk, Reliability and Quality
Human Factors and Ergonomics
And 37 more
About
Luke Connelly is Professor of Health Economics at the Centre for the Business and Economics of Health. He also holds a Professorial appointment (part-time) at The University of Bologna, to which he was appointed in 2017 via the Italian “Direct Call” ([link](https://www.unibo.it/sitoweb/luke.connelly/en)) process. In 2019 he was appointed as Honorary Professor at The University of Sydney. His main interests are in health economics and insurance economics and the effects of institutions (including legal constructs) on incentives and behaviour. He has also worked in other fields of applied microeconomics, including education economics and transport economics. His publications include papers in *Review of Income and Wealth*, *Health Economics*, *Journal of Health Economics*, *Journal of Risk and Insurance*, *Geneva Papers on Risk and Insurance*, *Accident Analysis and Prevention*, *Journal of Law and Medicine*, *Journal of Clinical Epidemiology*, *European Journal of Health Economics*, *International Journal of Health Economics and Finance*, *Social Science and Medicine*, *Economic Papers*, *Economic Analysis and Policy*, *Journal of Transport Economics and Policy*, *Labour Economics*, *Economics and Human Biology* as well as in a range of clinical journals, including *Lancet*. Luke has served on a number of public committees including the Medical Services Advisory Committee (MSAC), which advises the Australian Minister for Health on the safety, efficacy, effectiveness, and cost-effectiveness of new and extant listings on Australia's Medicare Benefits Schedule. He has extensive service on other public committees and taskforces as well as extensive teaching and consulting engagements with industry. Over his career he has been a chief investigator on research grants and contracts totalling more than $67m. He is a member of the Editorial Boards of European Journal of Health Economics and the International Journal on Environmental Research and Public Health. He is a member of the International Health Economics Association's Arrow Awards Committee, which awards an annual prize in honour of Nobel Laureate Kenneth Arrow for the best paper in the field. He is currently Guest Editor (with Christophe Courbage) on a Special Issue of the Geneva Papers on Risk and Insurance on Insurance and Emerging Health Risks. His current research interests include health service innovations to improve the health of people with chronic kidney disease(CKD). Ongoing interests include the economics of disability and insurance, compensable injury compensation schemes, and the determinants of health. Luke enjoys and has considerable experience teaching economics and health economics at both the graduate and undergraduate levels. In 2014 he was awarded the School of Economics Distinguished Teaching Award for his teaching on UQ's Master of Health Economics Program. In July 2016 and July 2019 he also taught summer schools in Health Economics and the Economics of Insurance at The University of Lucerne, Switzerland. Over the past 10 years he has been a chief investigator on grants totalling more than $70m.
Most Relevant Publications (1+)

105 total publications

Economic evaluation of fecal microbiota transplantation for the treatment of recurrentClostridium difficileinfection in Australia

Journal of Gastroenterology and Hepatology / Nov 29, 2016

Merlo, G., Graves, N., Brain, D., & Connelly, L. B. (2016). Economic evaluation of fecal microbiota transplantation for the treatment of recurrentClostridium difficileinfection in Australia. Journal of Gastroenterology and Hepatology, 31(12), 1927–1932. Portico. https://doi.org/10.1111/jgh.13402

See Full Profile

Roshonda Jones

Charlotte, North Carolina, United States of America
7 Years Experience
Bioinformatics research scientist using computational and statistical techniques to examine the relationship between diet, health and microbes
Education

University of North Carolina at Charlotte

Ph.D., Bioinformatics and Computational Biology / August, 2016

Charlotte, North Carolina, United States of America

North Carolina Agricultural and Technical State University

B.S., Applied Mathematics / May, 2011

Greensboro, North Carolina, United States of America
Experience

University of Southern California

Postdoctoral Scholar / September, 2016 — December, 2018

Childrens Hospital Los Angeles

Postdoctoral Research Fellow / January, 2019 — November, 2020

Most Relevant Research Expertise
Hepatology
Other Research Expertise (23)
Bioinfomatics
Microbiome
Childhood Obesity
Microbiology
Microbiology (medical)
And 18 more
About
Roshonda Jones is an experienced bioinformatics and computational biologist with a passion for exploring the complexities of life. She earned her Ph.D. in Bioinformatics and Computational Biology from University of North Carolina at Charlotte in 2016, and went on to complete a postdoctoral fellowship at USC, as well as a postdoctoral research fellowship at Children’s Hospital Los Angeles. Her research interests include machine learning and bioinformatics. She is committed to using her expertise to further scientific knowledge and advance the field.
Most Relevant Publications (1+)

43 total publications

Sa1801 Local Environmental Conditions Override NOD2-Mediated Regulatory Effects on Mouse Intestinal Microbial Composition

Gastroenterology / May 01, 2013

Carroll, I. M., Shanahan, M. T., Barner, R., Fodor, A. A., Sartor, R. B., & Gulati, A. S. (2013). Sa1801 Local Environmental Conditions Override NOD2-Mediated Regulatory Effects on Mouse Intestinal Microbial Composition. Gastroenterology, 144(5), S-309. https://doi.org/10.1016/s0016-5085(13)61112-9

See Full Profile

Giuliana Noratto

15 Years Experience
Food Scientist PhD and Registered Dietician - Texas A&M University
Education

Texas A&M University

Texas A&M University System

Ph.D., Department of Food Science and Technology

College Station

Universidad Nacional Agraria La Molina

M.Sc., Food Science and Technology

Lima
Experience

Texas A&M AgriLife

Senior Associate Research Scientist / August, 2016 — Present

Washington State

Assistant Professor - Head of Food Science lab / 2012 — 2016

Research focus is on the role of nutrition in the prevention or progress of obesity-related chronic diseases. We investigate food bioactive compounds with the main goal of uncovering the molecular mechanisms by which diet derived compounds interact with the genome (effect on gene and protein expression and biomarkers) to shift the onset or outcome of disease. Research projects are centered around: - Milk and dairy-derived bioactive compounds - Plant food botanicals

Texas A&M University

Research Scientist / 2008 — 2012

In charge of projects dealing with effects of natural plant extracts to prevent or cure cancer, diabetes, and cardiovascular complications; all these having in common to be the result of inflammation and obesity.

Research Expertise (29)
Food Science
Nutrition
Human Health
Analytical Chemistry
Nutrition and Dietetics
And 24 more
About
Dr. Giuliana Noratto is a senior associate research scientist at Texas A&M AgriLife. She received her Ph.D. in food science and technology from Texas A&M University System, and her M.Sc. in food science and technology from Universidad Nacional Agraria La Molina. She also holds a B.S. in food science and technology from Universidad Nacional Agraria La Molina. Dr. Noratto’s research interests include food safety and quality, sensory science, and food processing.

See Full Profile

James Boot, PhD

9 Years Experience
Bioinformatician at Queen Mary University of London, experienced in a wide variety of data analysis pipelines.
Education

University of Bath

BSc Biochemistry / August, 2016

Bath

Queen Mary University of London

Ph.D., Oncology and Cancer Biology / January, 2021

London
Experience

MedImmune

Industrial Placement Student / June, 2014 — June, 2015

Commencing July 2014, as part of my degree I undertook a year in industry, carrying out my own research project within the Oncology department of MedImmune. The project was focussed on assay development and utilising innovative 3D culture techniques.

PhoreMost

Intern Associate Scientist / July, 2015 — September, 2015

Ten weeks’ work experience at a new start-up company, based in Cambridge. I helped set up processes and systems in a new laboratory, the company moved into, this included health and safety procedures. I also helped purchase consumables and large equipment. Finally, I carried out wet lab work, mainly involving cloning, transformations, restriction digests and gel electrophoresis.

Queen Mary University of London

Bioinformatician / May, 2021 — Present

Bioinformatician in the Genome Centre core facility at Queen Mary, based at the Blizard Institute. I perform and support analyses of genomics data for clients, ranging from bulk RNAseq, scRNAseq, ATACseq, methylation, WGS, long read sequencing and more! Working across a variety of projects and modalities.

Most Relevant Research Expertise
Hepatology
Other Research Expertise (0)
About
PhD graduate from Queen Mary University of London, my research was undertaken in Professor Silvia Marino’s brain tumour research group. Specifically, I was part of a team researching Glioblastoma Multiforme, the most prevalent and deadly adult brain tumour. Throughout my PhD I developed my wet lab skills and learnt to code for the purpose of analysing high throughput sequencing data such as RNAseq and DNA methylation array data. Since finishing my PhD I have worked as a Bioinformatician in the Genome Centre at the Blizard Institute, QMUL, where I have built up a experience in a very wide variety of Bioinformatics pipelines and analyses for a variety of datasets.
Most Relevant Publications (1+)

3 total publications

Toll-like receptor 5 signalling mediates pro-inflammatory and fibrogenic responses in non-alcoholic steatohepatitis (NASH)

Journal of Hepatology / Jun 01, 2023

Li, W., Garrido, P., Mir, I. G., Waller, K., Jong, A. V., Brindley, J. H., Khan, W., Hood, G., Boot, J., Mein, C., Devalia, K., Loy, J., & Alazawi, W. (2023). Toll-like receptor 5 signalling mediates pro-inflammatory and fibrogenic responses in non-alcoholic steatohepatitis (NASH). Journal of Hepatology, 78, S740. https://doi.org/10.1016/s0168-8278(23)02141-4

See Full Profile

Dana Walsh, Ph.D.

8 Years Experience
Senior Microbiome Scientist at CosmosID
Education

University of North Carolina at Chapel Hill

Ph.D., Toxicology / May, 2016

Chapel Hill, North Carolina, United States of America

Concordia College - Minnesota

B.A., Biology / December, 2009

Moorhead, Minnesota, United States of America
Experience

CosmosID

Senior Microbiome Scientist / June, 2023 — Present

• Consult with clients to advise the best approach for their microbiome and metabolomics study design, sample collection and storage, sequencing and metabolomics methods, and bioinformatics and statistical analysis • Create custom analyses and reports helping clients understand their data • Manage and review scientific newsletters and blogs • Develop and test new methods for innovative data analysis • Promoted to senior microbiome scientist to lead custom project analysis and integration of new analysis methods and pipelines • Managed the bioinformatics team in sequencing production and project delivery

Microbiome Scientist / August, 2021 — June, 2023

• Identified the impact of microbiome-based therapeutics on subjects with Clostridioides difficile infection through analysis of micrbial community, functional, and metabolomics data • Established new methodologies for integration of complex microbial compositional, functional, and metabolomics data in the programming language R • Managed and developed relationships with microbiome analysis collaborators to drive high-quality and novel analysis methods and product development • Presented at least one oral talk per year at a national conference on the impact of biotherapeutics on the microbiome

NirvanaBiome

Microbiome Consultant / January, 2023 — Present

• Meet with customers (individuals and clinicians) to explain their gut microbiome test results • Provide a basic understanding of the gut microbiome and its importance in health along with individualized interpretation of results and recommendations of over-the-counter interventions that may help (such as the use of specific pre- and probiotics or dietary recommendations)

Rebiotix

Microbiome Analysis Scientist / June, 2019 — August, 2021

• Identified the impact of microbiome-based therapeutics on subjects with Clostridioides difficile infection through analysis of micrbial community, functional, and metabolomics data • Established new methodologies for integration of complex microbial compositional, functional, and metabolomics data in the programming language R • Managed and developed relationships with microbiome analysis collaborators to drive high-quality and novel analysis methods and product development • Presented at least one oral talk per year at a national conference on the impact of biotherapeutics on the microbiome

Most Relevant Research Expertise
Hepatology
Other Research Expertise (10)
microbiome
microbiology
gut health
infant microbiome
maternal microbiome
And 5 more
About
Dana Walsh is a Senior Microbiome Scientist at CosmosID, a leading company in microbial genomics and bioinformatics. With a PhD in Toxicology and more than five years of experience in microbiome research, she manages the bioinformatics team and assists clients with design, analysis, and interpretation of multiomics data. She has a strong background in both wet bench and computational research, and has applied novel analysis methods to derive meaning from microbial taxonomic, functional, and metabolomic data. In her previous role at Rebiotix, she supported the development of microbiome-based live biotherapeutic drugs for various diseases. She also completed a postdoctoral fellowship at Mayo Clinic, where she investigated the role of the microbiome in cancers of the reproductive tract. She is passionate about exploring the microbiome dynamics and applications in the industrial sector, with a current emphasis on maternal and infant health.
Most Relevant Publications (1+)

16 total publications

Mo1931 FAILURE IS NOT FINAL: CLINICAL RESPONSE AND MICROBIOME RESTORATION BY INVESTIGATIONAL DRUG RBX2660 ARE NOT COMPROMISED FOLLOWING PREVIOUS NON-RESPONSE FOR PREVENTING CLOSTRIDIOIDES DIFFICILE RECURRENCE

Gastroenterology / May 01, 2020

Steiner, T. S., Walsh, D. M., Gonzalez, C., Shannon, B., Su, X., & Blount, K. (2020). Mo1931 FAILURE IS NOT FINAL: CLINICAL RESPONSE AND MICROBIOME RESTORATION BY INVESTIGATIONAL DRUG RBX2660 ARE NOT COMPROMISED FOLLOWING PREVIOUS NON-RESPONSE FOR PREVENTING CLOSTRIDIOIDES DIFFICILE RECURRENCE. Gastroenterology, 158(6), S-982. https://doi.org/10.1016/s0016-5085(20)33128-0

See Full Profile

Marina Baretti

Baltimore, Maryland, United States of America
2 Years Experience
I am a clinical translational researcher in gastrointestinal (GI) oncology, collaborating closely with laboratory-based researchers to move laboratory findings into patients and to answer important clinical questions.
Experience

Johns Hopkins University

Co-Director of the Liver and Biliary Cancer Multidisciplinary Clinic at Johns Hopkins, Baltimore, MD / January, 2023 — Present

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins School of Medicine, Baltimore, MD

Assistant professor / October, 2021 — Present

Most Relevant Research Expertise
Hepatology
Other Research Expertise (14)
Oncology
Pharmacology (medical)
Pharmacology
Hematology
Gastroenterology
And 9 more
About
Throughout my training, I have been focused toward my ultimate goal of becoming a clinical translational researcher in gastrointestinal (GI) oncology, collaborating closely with laboratory-based researchers to move laboratory findings into patients and to answer important clinical questions. My clinical research is centered on the development of novel agents in GI cancers, with particular interest in combinatorial approaches of epigenetic therapies and immunotherapies combinations. I ran the first phase II study of combination epigenetic therapy and immunotherapy in advanced pancreatic adenocarcinoma and cholangiocarcinoma, working with a collaborative team that incorporates leading experts in cancer immunology, epigenetics and drug development. I was awarded the 2018 ASCO Conquer Cancer Foundation Young Investigator Award for this project.  Together with Dr. Yarchoan, we are running a clinical trial of a novel neoantigen-specific vaccine in combination with immune checkpoint inhibitors for advanced fibrolamellar carcinoma (FLC) (NCT04248569). My laboratory focus has been on developing and validating a preclinical mouse model of FLC to investigate mechanisms underlying FLC pathogenesis, and will become a critical tool for investigating novel therapeutic strategies in FLC.
Most Relevant Publications (4+)

54 total publications

Clinical value of chip-based digital-PCR platform for the detection of circulating DNA in metastatic colorectal cancer

Digestive and Liver Disease / Oct 01, 2015

Sefrioui, D., Sarafan-Vasseur, N., Beaussire, L., Baretti, M., Gangloff, A., Blanchard, F., Clatot, F., Sabourin, J.-C., Sesboüé, R., Frebourg, T., Michel, P., & Di Fiore, F. (2015). Clinical value of chip-based digital-PCR platform for the detection of circulating DNA in metastatic colorectal cancer. Digestive and Liver Disease, 47(10), 884–890. https://doi.org/10.1016/j.dld.2015.05.023

Prognostic Implications of the Immune Tumor Microenvironment in Patients With Pancreatic and Gastrointestinal Neuroendocrine Tumors

Pancreas / May 01, 2021

Baretti, M., Zhu, Q., Zahurak, M., Bhaijee, F., Xu, H., Engle, E. L., Kotte, A., Pawlik, T. M., Anders, R. A., & De Jesus-Acosta, A. (2021). Prognostic Implications of the Immune Tumor Microenvironment in Patients With Pancreatic and Gastrointestinal Neuroendocrine Tumors. Pancreas, 50(5), 719–726. https://doi.org/10.1097/mpa.0000000000001831

Surgical Debulking for Refractory Hyperammonemic Encephalopathy in Fibrolamellar Hepatocellular Carcinoma

Hepatology / Aug 21, 2021

Solipuram, V., Baretti, M., Kim, A. Y., Chen, L. X., Fahrner, J. A., Gunay‐Aygun, M., Peng, X. P., Hardenbergh, D., Ferguson, A., Griffith, P., Wang, Y., Brancati, M., Gopalakrishna, H., Kato, T., Shubert, C., Laheru, D., & Yarchoan, M. (2021). Surgical Debulking for Refractory Hyperammonemic Encephalopathy in Fibrolamellar Hepatocellular Carcinoma. Hepatology, 74(5), 2899–2901. https://doi.org/10.1002/hep.31998

The Significance of Ascites in Patients With Pancreatic Ductal Adenocarcinoma

Pancreas / Apr 01, 2019

Baretti, M., Pulluri, B., Tsai, H.-L., Blackford, A. L., Wolfgang, C. L., Laheru, D., Zheng, L., Herman, J., Le, D. T., Narang, A. K., & de Jesus-Acosta, A. (2019). The Significance of Ascites in Patients With Pancreatic Ductal Adenocarcinoma. Pancreas, 48(4), 585–589. https://doi.org/10.1097/mpa.0000000000001262

See Full Profile

Leo R Fitzpatrick PhD

Greenwood , South Carolina, United States of America
37 Years Experience
GI Pharmacology and IBD Research Consultant
Education

PhD, Physiology

Post Doctoral Fellowship, GI Physiology

Experience

California NorthState University

Penn State College of Medicine

Otsuka Pharmaceutical

Most Relevant Research Expertise
Hepatology
Other Research Expertise (32)
Inflammatory Bowel Disease
Colitis
Arthritis
Surgery
Immunology
And 27 more
About
Please see my CV for details. I have 37 years of GI and IBD Research experience. This includes both industry and academic experience.
Most Relevant Publications (28+)

89 total publications

CAPE, an inhibitor of nuclear factor-kappa B (NF-κB), attenuates bacterial peptidoglycan polysaccharide (PG-PS) induced colitis in rats

Gastroenterology / Apr 01, 2001

FITZPATRICK, L., WANG, J., & LE, T. (2001). CAPE, an inhibitor of nuclear factor-kappa B (NF-κB), attenuates bacterial peptidoglycan polysaccharide (PG-PS) induced colitis in rats. Gastroenterology, 120(5), A685–A685. https://doi.org/10.1016/s0016-5085(01)83409-0

CAPE, an inhibitor of nuclear factor-kappa B (NF-κB), attenuates bacterial peptidoglycan polysaccharide (PG-PS) induced colitis in rats

Gastroenterology / Apr 01, 2001

Fitzpatrick, L. R., Wang, J., & Le, T. (2001). CAPE, an inhibitor of nuclear factor-kappa B (NF-κB), attenuates bacterial peptidoglycan polysaccharide (PG-PS) induced colitis in rats. Gastroenterology, 120(5), A685. https://doi.org/10.1016/s0016-5085(08)83409-9

Effect of epidermal growth factor on polyamine-synthesizing enzymes in rat enterocytes

American Journal of Physiology-Gastrointestinal and Liver Physiology / Feb 01, 1987

Fitzpatrick, L. R., Wang, P., & Johnson, L. R. (1987). Effect of epidermal growth factor on polyamine-synthesizing enzymes in rat enterocytes. American Journal of Physiology-Gastrointestinal and Liver Physiology, 252(2), G209–G214. https://doi.org/10.1152/ajpgi.1987.252.2.g209

Effect of refeeding on polyamine biosynthesis in isolated enterocytes

American Journal of Physiology-Gastrointestinal and Liver Physiology / May 01, 1986

Fitzpatrick, L. R., Wang, P., Eikenburg, B. E., Haddox, M. K., & Johnson, L. R. (1986). Effect of refeeding on polyamine biosynthesis in isolated enterocytes. American Journal of Physiology-Gastrointestinal and Liver Physiology, 250(5), G709–G713. https://doi.org/10.1152/ajpgi.1986.250.5.g709

Relationship between ornithine decarboxylase activity and gastric damage

American Journal of Physiology-Gastrointestinal and Liver Physiology / Dec 01, 1987

Thirumalai, C. H., Tseng, C. C., Tabata, K., Fitzpatrick, L. R., & Johnson, L. R. (1987). Relationship between ornithine decarboxylase activity and gastric damage. American Journal of Physiology-Gastrointestinal and Liver Physiology, 253(1), G1–G6. https://doi.org/10.1152/ajpgi.1987.253.1.g1

T2035 The Novel Probiotic Escherichia coli Strain M-17 Uniquely Inhibits Pro-Inflammatory Cytokine Secretion in Macrophage and Colonic Epithelial Cell Lines

Gastroenterology / May 01, 2010

Fitzpatrick, L. R., Small, J. S., Bostwick, E. F., & Hoerr, R. A. (2010). T2035 The Novel Probiotic Escherichia coli Strain M-17 Uniquely Inhibits Pro-Inflammatory Cytokine Secretion in Macrophage and Colonic Epithelial Cell Lines. Gastroenterology, 138(5), S-618. https://doi.org/10.1016/s0016-5085(10)62848-x

Amiloride inhibits rat mucosal ornithine decarboxylase activity and DNA synthesis

American Journal of Physiology-Gastrointestinal and Liver Physiology / Mar 01, 1988

Ulrich-Baker, M. G., Wang, P., Fitzpatrick, L., & Johnson, L. R. (1988). Amiloride inhibits rat mucosal ornithine decarboxylase activity and DNA synthesis. American Journal of Physiology-Gastrointestinal and Liver Physiology, 254(3), G408–G415. https://doi.org/10.1152/ajpgi.1988.254.3.g408

Indomethacin‐induced gastric antral damage in hamsters: are neutrophils involved?

Alimentary Pharmacology & Therapeutics / Feb 01, 1999

Fitzpatrick, Sakurai, & Le. (1999). Indomethacin‐induced gastric antral damage in hamsters: are neutrophils involved? Alimentary Pharmacology & Therapeutics, 13(2), 195–202. Portico. https://doi.org/10.1046/j.1365-2036.1999.00444.x

Inhibition of IL-17 Release by the Novel Anti-Inflammatory Drug Vidofludimus Involves Attenuation of STAT3 and NF-kappa B Signaling Pathways in Murine Splenocytes and Hapten-Induced Colitis

Gastroenterology / May 01, 2011

Fitzpatrick, L. R., Small, J. S., & Ammendola, A. (2011). Inhibition of IL-17 Release by the Novel Anti-Inflammatory Drug Vidofludimus Involves Attenuation of STAT3 and NF-kappa B Signaling Pathways in Murine Splenocytes and Hapten-Induced Colitis. Gastroenterology, 140(5), S-837. https://doi.org/10.1016/s0016-5085(11)63470-7

Effect of naproxen on the hamster gastric antrum: ulceration, adaptation and efficacy of anti‐ulcer drugs

Alimentary Pharmacology & Therapeutics / Nov 01, 1999

Fitzpatrick, Sakurai, & Le. (1999). Effect of naproxen on the hamster gastric antrum: ulceration, adaptation and efficacy of anti‐ulcer drugs. Alimentary Pharmacology & Therapeutics, 13(11), 1553–1562. Portico. https://doi.org/10.1046/j.1365-2036.1999.00624.x

M1658 A Novel Immunosuppressive Drug (4SC-101) Improves TNBS-Induced Colitis in Mice

Gastroenterology / May 01, 2009

Fitzpatrick, L. R., Small, J. S., Zhang, G., & Jankowsky, R. (2009). M1658 A Novel Immunosuppressive Drug (4SC-101) Improves TNBS-Induced Colitis in Mice. Gastroenterology, 136(5), A-404. https://doi.org/10.1016/s0016-5085(09)61857-6

The modulatory effects of plasma and colonic milieu of patients with ulcerative colitis on OPC antioxidant

The American Journal of Gastroenterology / Sep 01, 2001

FARHADI, A. (2001). The modulatory effects of plasma and colonic milieu of patients with ulcerative colitis on OPC antioxidant. The American Journal of Gastroenterology, 96(9), S290. https://doi.org/10.1016/s0002-9270(01)03699-1

Fos expression in the colonic myenteric plexus induced by water avoidance stress in different rat strains

Gastroenterology / Apr 01, 2001

MIAMPAMBA, M., MILLION, M., & TACHE, Y. (2001). Fos expression in the colonic myenteric plexus induced by water avoidance stress in different rat strains. Gastroenterology, 120(5), A715–A715. https://doi.org/10.1016/s0016-5085(01)83560-5

Tu1744 - Ex Vivo Effects of Ror-Gamma T Inhibitors on Proinflammatory Cytokine Secretion from Colonic Strips of Mice with DSS-Induced Colitis

Gastroenterology / May 01, 2018

Fitzpatrick, L. R., Talbott, G., Buhr, C. A., Alton, G., & Zapf, J. (2018). Tu1744 - Ex Vivo Effects of Ror-Gamma T Inhibitors on Proinflammatory Cytokine Secretion from Colonic Strips of Mice with DSS-Induced Colitis. Gastroenterology, 154(6), S-1007-S-1008. https://doi.org/10.1016/s0016-5085(18)33370-5

A Novel ROR-Gamma T Inhibitor (VPR-254) Attenuates Key Parameters of Innate Immune Colitis in Mice

Gastroenterology / Apr 01, 2017

Fitzpatrick, L. R., O’Connell, R., Talbott, G., Bendele, P., Alton, G., & Zapf, J. (2017). A Novel ROR-Gamma T Inhibitor (VPR-254) Attenuates Key Parameters of Innate Immune Colitis in Mice. Gastroenterology, 152(5), S30–S31. https://doi.org/10.1016/s0016-5085(17)30468-7

Sa1834 Effects of Silymarin Fractions on Pro-Inflammatory Cytokine Secretion from Macrophage and Colonic Epithelial Cell Lines

Gastroenterology / Apr 01, 2016

Fitzpatrick, L. R., Talbott, G., & Woldemariam, T. (2016). Sa1834 Effects of Silymarin Fractions on Pro-Inflammatory Cytokine Secretion from Macrophage and Colonic Epithelial Cell Lines. Gastroenterology, 150(4), S376–S377. https://doi.org/10.1016/s0016-5085(16)31323-3

90 Efficacy of a Novel Small Molecule RORgt Inverse Agonist in Mouse DSS and TNBS Models of Inflammatory Bowel Disease

Gastroenterology / Apr 01, 2015

Fitzpatrick, L. R., Zapf, J., Flood, E. M., Ravula, S. B., Lingardo, L. K., Small, J., Tucci, F., Buhr, C. A., & Alton, G. (2015). 90 Efficacy of a Novel Small Molecule RORgt Inverse Agonist in Mouse DSS and TNBS Models of Inflammatory Bowel Disease. Gastroenterology, 148(4), S-26. https://doi.org/10.1016/s0016-5085(15)30090-1

Sa2053 Bacillus Coagulans Bc30 Limits the Recurrence of Clostridium diJicile-Induced Colitis Following Vancomycin Withdrawal in Mice

Gastroenterology / May 01, 2012

Fitzpatrick, L. R., Small, J. S., Greene, W., Karpa, K., & Keller, D. (2012). Sa2053 Bacillus Coagulans Bc30 Limits the Recurrence of Clostridium diJicile-Induced Colitis Following Vancomycin Withdrawal in Mice. Gastroenterology, 142(5), S-390. https://doi.org/10.1016/s0016-5085(12)61479-6

M1651 Melanin-Concentrating Hormone Receptor 1 Antagonists Attenuate TNBS-Induced Colitis in Mice

Gastroenterology / May 01, 2009

Fitzpatrick, L. R., Small, J. S., & Zhang, G. (2009). M1651 Melanin-Concentrating Hormone Receptor 1 Antagonists Attenuate TNBS-Induced Colitis in Mice. Gastroenterology, 136(5), A-403. https://doi.org/10.1016/s0016-5085(09)61850-3

A comparison of sucralfate and bismuth subsalicylate formulations in rabbit esophageal models

Gastroenterology / Apr 01, 1995

A comparison of sucralfate and bismuth subsalicylate formulations in rabbit esophageal models. (1995). Gastroenterology, 108(4), A94. https://doi.org/10.1016/0016-5085(95)23040-8

Tu1617 The Synthetic Triterpenoid (CDDO-IM) Inhibits STAT3, As Well As IL-17, and Improves DSS-Induced Colitis in Mice

Gastroenterology / May 01, 2013

Stonesifer, E., Fitzpatrick, L. R., Small, J., & Liby, K. T. (2013). Tu1617 The Synthetic Triterpenoid (CDDO-IM) Inhibits STAT3, As Well As IL-17, and Improves DSS-Induced Colitis in Mice. Gastroenterology, 144(5), S-807. https://doi.org/10.1016/s0016-5085(13)62986-8

Bacillus Coagulans (Bc 30 ) Improves Some Indices of Clostridium difficile -Induced Colitis in Mice

Gastroenterology / May 01, 2011

Fitzpatrick, L. R., Small, J. S., Greene, W., Karpa, K., & Keller, D. (2011). Bacillus Coagulans (Bc 30 ) Improves Some Indices of Clostridium difficile -Induced Colitis in Mice. Gastroenterology, 140(5), S-849. https://doi.org/10.1016/s0016-5085(11)63523-3

Characterization of the reactivation phase of dextran sodium sulfate (DSS)-induced colitis in rats

Gastroenterology / Apr 01, 1998

Fitzpatrick, L. R., Williams, J., & Le. Maryland, T. (1998). Characterization of the reactivation phase of dextran sodium sulfate (DSS)-induced colitis in rats. Gastroenterology, 114, A976. https://doi.org/10.1016/s0016-5085(98)83975-9

Novel characterization and quantification of bismuth binding to gastric mucosa

Gastroenterology / Apr 01, 1995

Novel characterization and quantification of bismuth binding to gastric mucosa. (1995). Gastroenterology, 108(4), A180. https://doi.org/10.1016/0016-5085(95)23381-4

Regulation of intestinal ornithine decarboxylase (ODC) expression during postnatal development by ODC antizyme in rats

Gastroenterology / Apr 01, 2000

Lin, C.-H., Tolia, V. K., & Vijesurier, R. M. (2000). Regulation of intestinal ornithine decarboxylase (ODC) expression during postnatal development by ODC antizyme in rats. Gastroenterology, 118(4), A292. https://doi.org/10.1016/s0016-5085(00)83253-9

Ex Vivo Effects of Silymarin Fractions on Pro-Inflammatory Cytokine Secretion from Colonic Strips of Mice with Dssinduced Colitis

Gastroenterology / Apr 01, 2017

Fitzpatrick, L. R., Talbott, G., Mokrushin, E., & Woldemariam, T. (2017). Ex Vivo Effects of Silymarin Fractions on Pro-Inflammatory Cytokine Secretion from Colonic Strips of Mice with Dssinduced Colitis. Gastroenterology, 152(5), S571. https://doi.org/10.1016/s0016-5085(17)32067-x

Colitis Development in IL-10 Deficient Mice Reveals a Direct Role of MCH in Regulating IL-10 Expression by Monocytes

Gastroenterology / May 01, 2011

Ziogas, D., ElKhal, A., Najarian, R. M., Mustafa, S. N., Reizes, O., Fitzpatrick, L. R., & Kokkotou, E. (2011). Colitis Development in IL-10 Deficient Mice Reveals a Direct Role of MCH in Regulating IL-10 Expression by Monocytes. Gastroenterology, 140(5), S-518. https://doi.org/10.1016/s0016-5085(11)62150-1

S1743 Efficacy of a Sphingosine Kinase Inhibitor in the Treatment of 2,4,6-Trinitrobenezenesulfonic Acid (TNBS)-Induced Colitis in Rats

Gastroenterology / Apr 01, 2008

Maines, L. W., Fitzpatrick, L. R., Green, C., & Smith, C. D. (2008). S1743 Efficacy of a Sphingosine Kinase Inhibitor in the Treatment of 2,4,6-Trinitrobenezenesulfonic Acid (TNBS)-Induced Colitis in Rats. Gastroenterology, 134(4), A-261. https://doi.org/10.1016/s0016-5085(08)61214-7

See Full Profile

Elham Shirvani-Dastgerdi

5 Years Experience
Enthusiastic scientist with 15+ years of research experience in Molecular biology and cell and gene therapy
Education

Princeton University

postdoc, Molecular Biology / June, 2019

Princeton, New Jersey, United States of America
Experience

Regeneron Pharmaceutical

Precision Medicine Strategy lead / March, 2023 — Present

Castle Creek Biosciences

Principal scientist / July, 2021 — March, 2023

Johnson & Johnson

Scientist / June, 2019 — June, 2021

Most Relevant Research Expertise
Hepatology
Other Research Expertise (13)
Virology
Biotechnology
Molecular Biology
Infectious Diseases
Microbiology (medical)
And 8 more
About
Enthusiastic scientist with 15+ years of research experience in Molecular biology, Virology and cell and gene therapy in industry and academic environments. Expert in developing strong working relationships with leading researchers and healthcare providers to address scientific needs. Possess in depth knowledge in infectious disease, immune responses, and vaccines; with excellent oral and written communication skills as demonstrated by research manuscripts published in high-impact journals and oral presentations in national and international conferences. Efficient, self-motivated, detail-oriented, team-worker with exceptional analytical problem-solving ability, and strong planning and organizational skills; experienced in working on fast-paced, challenging projects. Strong leadership in conducting multiple projects simultaneously and in a cross-functional team to complete scientific projects in a timely manner. <br>
Most Relevant Publications (3+)

18 total publications

Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy

Journal of Hepatology / Aug 01, 2017

Shirvani-Dastgerdi, E., Winer, B. Y., Celià-Terrassa, T., Kang, Y., Tabernero, D., Yagmur, E., Rodríguez-Frías, F., Gregori, J., Luedde, T., Trautwein, C., Ploss, A., & Tacke, F. (2017). Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy. Journal of Hepatology, 67(2), 246–254. https://doi.org/10.1016/j.jhep.2017.03.027

Impact of Drug-Resistance Polymerase Mutations on the Replication of HBeAg-Positive and HBeAg-Negative Hepatitis B Virus Strains in Vitro

Hepatitis Monthly / Jun 01, 2012

Tacke, F., & Shirvani-Dastgerdi, E. (2012). Impact of Drug-Resistance Polymerase Mutations on the Replication of HBeAg-Positive and HBeAg-Negative Hepatitis B Virus Strains in Vitro. Hepatitis Monthly, 12(6), 357–360. https://doi.org/10.5812/hepatmon.6131

Hepatitis E Virus Infection in Macaca Mulatta

Hepatitis Monthly / Sep 30, 2011

Dastgerdi, E. S., & Amini-Bavil-Olyaee, S. (2011). Hepatitis E Virus Infection in Macaca Mulatta. Hepatitis Monthly, 11(10), 852–853. https://doi.org/10.5812/kowsar.1735143x.783

See Full Profile

Emma Hernandez-Sanabria

11 Years Experience
Microbiome Research & Strategy | Exploring data, delivering innovation | Industry collabs | Fermentation!
Experience

BaseClear BV

Product Manager Animal Health and Performance / June, 2022 — Present

Katholieke Universiteit Leuven Rega Institute for Medical Research

Postdoctoral Fellow / October, 2019 — May, 2022

Universiteit Gent

Postdoctoral Fellow / May, 2013 — October, 2019

Most Relevant Research Expertise
Hepatology
Other Research Expertise (31)
Host-microbe interactions
gut microbiome
in vitro models
gut microbiota
Biotechnology
And 26 more
About
Driven by curiosity and innovation. Passionate about mentoring. Translating microbiome knowledge and technical details into project plans and results for a wide range of stakeholders, including commercial customers, academic partners, and internal teams, for over 12 years! My core competencies include stakeholder analysis and management, negotiation skills, team building and training, coaching and empowering research staff, interpreting critical industry data, and redesigning and troubleshooting systems for increased productivity and/or functionality. I have used a variety of techniques to explore host-microbe-environment interactions, such as in vitro gut fermentation models, bioinformatics and statistical tools, high-throughput molecular techniques, culturing techniques, flow cytometry, and microbial metabolite analysis. Let's connect and explore how my expertise in animal health and microbial genomics can drive solutions for your organization!
Most Relevant Publications (1+)

52 total publications

In vitro ecology: a discovery engine for microbiome therapies

Nature Reviews Gastroenterology &amp; Hepatology / Sep 15, 2020

Hernandez-Sanabria, E., Vázquez-Castellanos, J. F., & Raes, J. (2020). In vitro ecology: a discovery engine for microbiome therapies. Nature Reviews Gastroenterology &amp; Hepatology, 17(12), 711–712. https://doi.org/10.1038/s41575-020-00364-7

See Full Profile

Pranshu Sahgal, Ph.D.

10 Years Experience
Cell and Molecular biologist in cancer biology
Education

University of Turku

Ph.D., Cell and molecular biology / November, 2018

Turku
Experience

Dana-Farber Cancer Institute and Harvard Medical School

Most Relevant Research Expertise
Hepatology
Other Research Expertise (17)
Cancer Biology
Cancer Signaling
Cancer Genomics
Drug Discovery and Development
Cell Biology
And 12 more
About
·         Cell and Molecular Biologist with a robust background in translational research, specializing in identifying novel molecular biomarkers, drug targets, and mechanism of action for advancing early cancer diagnosis and targeted cancer treatment. ·         Recognized for a proven track record of scientific innovation, evidenced by: ○        15+ scientific papers (6 as first/co-first author) having direct clinical development implications; 800+ citations. ○        20+ new collaborations; Presentations of scientific data in 10+ national/international conferences. ○        $350,000 as personal grant award acquisition from 10 foundations. ·         Exemplary collaborator and communicator with deep expertise in latest culture models, molecular biology techniques, assay development and Good Laboratory Practice (GLP). Demonstrated ability to effectively manage multiple projects, exhibiting exceptional organizational skills and keen attention to detail, leveraging innovative thinking to drive research forward. ·         Certified Medical Affairs Specialist with an understanding of clinical study and trials, contributing to regulatory submissions and fostering relationships with Key Opinion Leaders (KOLs), Contract Research Organizations (CROs), and other key stakeholders.
Most Relevant Publications (1+)

20 total publications

An Enhancer-Driven Stem Cell–Like Program Mediated by SOX9 Blocks Intestinal Differentiation in Colorectal Cancer

Gastroenterology / Jan 01, 2022

Liang, X., Duronio, G. N., Yang, Y., Bala, P., Hebbar, P., Spisak, S., Sahgal, P., Singh, H., Zhang, Y., Xie, Y., Cejas, P., Long, H. W., Bass, A. J., & Sethi, N. S. (2022). An Enhancer-Driven Stem Cell–Like Program Mediated by SOX9 Blocks Intestinal Differentiation in Colorectal Cancer. Gastroenterology, 162(1), 209–222. https://doi.org/10.1053/j.gastro.2021.09.044

See Full Profile

Example hepatology projects

How can companies collaborate more effectively with researchers, experts, and thought leaders to make progress on hepatology?

Drug Development and Clinical Trials

An academic researcher in hepatology can contribute to the development of new drugs and therapies for liver diseases. They can design and conduct clinical trials, analyze data, and provide valuable insights into the efficacy and safety of potential treatments.

Diagnostic Tools and Biomarkers

Collaborating with a hepatology expert can lead to the development of advanced diagnostic tools and biomarkers for liver diseases. These tools can improve early detection, prognosis, and personalized treatment strategies, ultimately benefiting patients and healthcare providers.

Genomic and Proteomic Research

Hepatology researchers can contribute to genomic and proteomic studies focused on understanding the molecular mechanisms underlying liver diseases. This knowledge can help identify novel therapeutic targets and biomarkers, paving the way for precision medicine approaches.

Liver Disease Epidemiology

Academic researchers in hepatology can collaborate with companies to conduct epidemiological studies on liver diseases. This research can provide valuable insights into disease prevalence, risk factors, and trends, enabling companies to develop targeted prevention and intervention strategies.

Healthcare Policy and Guidelines

Companies can benefit from the expertise of hepatology researchers in shaping healthcare policies and guidelines related to liver diseases. Their insights can contribute to the development of evidence-based practices, improved patient care, and better allocation of healthcare resources.